by Madaline Spencer | Nov 6, 2024
Teresa Gidaro, Director of Clinical Development for NMD Pharma, discusses the SYNAPSE-CMT clinical trial testing NMD670 in the treatment of Charcot-Marie-Tooth (CMT) disease. CMT disease is a type of peripheral neuropathy, a condition affecting the transmission...
by Madaline Spencer | Nov 5, 2024
Niklas Huntemann, University Hospital of Düsseldorf, discusses real-world experience with therapies targeting either the complement system (C5) or neonatal Fc receptor (FcRn) in patients with myasthenia gravis (MG). MG is a chronic autoimmune...
by Madaline Spencer | Nov 4, 2024
Michelle Mellion, MD, Chief Medical Officer at PepGen, discusses results from the CONNECT2-EDO51 study testing the safety and efficacy of PGN-EDO51 in people with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. DMD affects the muscles,...
by Madaline Spencer | Nov 1, 2024
Louie Lee, PhD, Neurological Physiotherapist at University College London, discusses clinicians’ perspectives on implementing self-management support programs for people with neuromuscular disorders. Implementing self-management support programs...
by Madaline Spencer | Oct 30, 2024
Real-world data on Orladeyo (berotralstat) was presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Boston. This new data provides insight on berotralstat’s effectiveness in managing hereditary angioedema...
